Indication

In combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.

Medicine details

Medicine name:
ivosidenib (Tibsovo)
SMC ID:
SMC2615
Pharmaceutical company
Servier Laboratories Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
11 March 2024
SMC meeting date:
06 February 2024
Patient group submission deadline:
TBC